New approaches in the pharmacotherapy of posttraumatic stress disorder.
Posttraumatic stress disorder (PTSD) may develop after exposure to severe stress, such as combat, accidents, assaults, and natural disasters. Pharmacotherapy can be a useful adjunct in the comprehensive treatment of these patients. The presence of comorbid conditions, including depression, panic disorder, substance abuse, and traumatic brain injury, should be carefully evaluated. Symptoms of PTSD that are associated with central nervous system hyperarousal or reexperiencing of the traumatic event appear to be the most responsive to pharmacotherapy. Social withdrawal and dulled responsiveness have not been shown to be alleviated through standard pharmacologic interventions. A therapeutic strategy is proposed that is based on the patient's symptoms and initial response to medication.
Silver
J M
JM
Columbia-Presbyterian Medical Center, New York, N.Y.
Sandberg
D P
DP
Hales
R E
RE
D000525:Alprazolam / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D002220:Carbamazepine / Q000627:therapeutic use; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D016651:Lithium Carbonate; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy* / Q000523:psychology
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D016651:Lithium Carbonate; D002220:Carbamazepine; D008094:Lithium; D000525:Alprazolam